Login to Your Account

Clinic Roundup

Friday, January 21, 2011
Allos Therapeutics Inc., of Westminster, Colo., said data from the Phase II PROPEL study published in the Journal of Clinical Oncology showed that Folotyn (pralatrexate) in relapsed or refractory peripheral T-cell lymphoma patients produced an overall response rate of 29 percent, with 11 percent of patients experiencing a complete response or unconfirmed complete response. Folotyn was granted accelerated approval in PTCL in 2009.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription